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Objective: Our aim was to assess the usefulness of glomerular ﬁltration rate (GFR) and urinary
albumin excretion (UAE) to predict the risk of mortality in patients with type 2 diabetes
mellitus.
Material and methods: This is a prospective cohort study in patients with type 2 diabetes
mellitus. Clinical end-point was mortality rate. GFR was measured in ml/min/1.73 m2 and
stratiﬁed in 3 categories (≥60; 45–59; <45); UAE was measured in mg/24 h and was also strat-
iﬁed in 3 categories (<30; 30–300; >300). Mortality rates were reported per 1000 patient-years.
Cox  regression models were used to predict mortality risk associated with combined GFR
and  UAE. The predictive power was estimated with C-Harrell statistic.
Results: A total of 453 patients (39.3% males), aged 64.9 (SD 9.3) years were included; mean
diabetes duration was 10.4 (SD 7.5) years. Median follow-up was 13 years. Total mortality
rate  was 39.5/1000. The progressive increase in mortality in the successive categories of
GFR  and UAE was statistically signiﬁcant (P < .001). In a multivariable analysis, UAE (HR30-
300  = 1.02 and HR > 300 = 2.83; 2 = 11.6; P = .003) and GFR (HR45-59 = 1.34 and HR < 45 = 1.84;
2 = 6.4; P = .041) were independent predictors for mortality, with no signiﬁcant interaction.
Simultaneous inclusion of GFR and UAE improved the predictive power of models (C-Harrell
0.741  vs. 0.726; P = .045).
Conclusions: GFR and UAE are independent predictors for mortality in type 2 diabetic patients
and do not show a statistically signiﬁcant interaction.©  2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española
de  Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
DOI of original article:
ttp://dx.doi.org/10.1016/j.nefro.2015.05.025.
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Riesgo  de  mortalidad  asociado  a  enfermedad  renal  crónica  en  pacientes
con  diabetes  tipo  2  durante  un  seguimiento  de  13  an˜os
Palabras clave:
Diabetes mellitus tipo 2
Insuﬁciencia renal crónica
Mortalidad
r  e  s  u  m  e  n
Objetivos: Nuestro objetivo fue evaluar la inﬂuencia de la tasa de ﬁltración glomerular (TFG)
y  de la excreción de albúmina urinaria (EAU) sobre el riesgo de mortalidad en pacientes con
diabetes mellitus tipo 2 (DM2).
Material y métodos: Estudio de cohortes prospectivo con inclusión de pacientes con DM2. El
punto ﬁnal clínico fue mortalidad total. La TFG se midió en ml/min/1,73 m2 con estratiﬁ-
cación en 3 categorías (≥60; 45-59; <45) y la EAU en mg/24 h con estratiﬁcación también en
3  categorías (<30; 30-300; >300).
Se evaluaron las tasas de mortalidad por cada 1.000 pacientes/an˜o y, mediante regresión de
Cox, el riesgo de mortalidad asociado con las categorías de TFG y EAU. El poder predictivo
se  midió con el estadístico C de Harrell.
Resultados: Se incluyó a 453 pacientes (39,3% varones, edad 64,9 [DE 9,3] an˜os y evolución de
DM2  10,4 [DE 7,5] an˜os). Durante una mediana de 13 an˜os de seguimiento, la tasa de mortali-
dad  total fue de 39,5/1.000, con incremento progresivo ante descenso de la TFG y aumento de
la  EAU (p < 0,001). En análisis multivariante la EAU (HR30-300 = 1,02 y HR>300 = 2,83; chi2 = 11,6;
p  = 0,003) y la TFG (HR45-59 = 1,34 y HR<45= 1,84; chi2 = 6,4; p = 0,041) fueron predictores inde-
pendientes de mortalidad sin interacción signiﬁcativa. La inclusión de TFG y EAU mejoró la
capacidad predictiva de los modelos (C de Harrell 0,741 vs. 0,726; p = 0,045).
Conclusiones: La TFG y la EAU son predictores independientes de mortalidad en pacientes
con DM2, sin interacción signiﬁcativa.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de  Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
Baseline  examinationIntroduction
The presence of diabetes mellitus (DM) increases patients’
cardiovascular risk and it is considered to be equivalent to
coronary heart disease risk.1 However, not all patients with
DM have the same cardiovascular risk.2 It is widely known that
the presence of chronic kidney disease (CKD) increases the
risk of overall mortality and cardiovascular mortality (CVM)
in the general population. This increased risk is associated to
both increased urinary albumin excretion (UAE) and reduced
glomerular ﬁltration rate (GFR). These two variables provide
independent information.3
Patients with diabetic nephropathy have CVM rates well
above the very high risk4 threshold that has been deﬁned
by the European Society of Cardiology (ESC) guidelines.5 Due
to their prognostic signiﬁcance, monitoring of both GFR and
UAE is recommended in follow-up of patients with DM.6,7 Fur-
thermore, it is recognised that in DM patients with CKD the
approach to reduce the increased cardiovascular risk, should
be multidisciplinary.
In the review by the Chronic Kidney Disease Prognosis
Consortium,3 most of the studies included that assessed mor-
tality risk in association with the presence of CKD were of less
than 10 years’ duration and did not include populations from
Spain.
The aims of our study, using long-term follow-up of a
cohort of patients with type 2 DM,  were:1. To describe mortality rates as a function of GFR, UAE, and
the combination of the two variables.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. To ascertain that GFR and UAE offer independent informa-
tion on patient mortality risk at long-term follow-up.
Materials  and  methods
Design
A prospective cohort study.
Study  population
This is described in detail in previous articles.8,9 Between 1
June 1994 and 1 June 1998, we  selected 463 patients with type 2
DM being followed as endocrinology outpatients at the Hospital
Comarcal de Alcan˜iz  (Alcan˜iz district hospital). This hospital has
a referral population of 70,000 patients.
The inclusion criteria were: diabetes diagnosed using
the World Health Organisation criteria valid at the time of
diagnosis,10 older than 35 years at the time of diagnosis, and
absence of treatment with insulin for at least 1 year after
diagnosis. Exclusion criteria were: severe somatic disease,
pregnancy, uncontrolled hyperthyroidism or hypothyroidism,
systemic corticoid treatment, or advanced renal failure (creati-
nine greater than 3 mg/dL). The study design was approved by
the hospital ethics committee, and all participants gave their
verbal consent before being enrolled.On enrolment, patients were interviewed, noting their age,
sex, known time with DM, smoking habits (active smoker,
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x-smoker, or nonsmoker), DM treatment (diet, oral hypogly-
aemics, or insulin) and any manifestation of existing vascular
isease (ischaemic heart disease, lower limb ischaemia, or
erebrovascular disease). Physical examination included mea-
urement of weight and height (and calculation of body
ass index, deﬁned as weight in kg/[height in metres]
quared), and systolic and diastolic blood pressure, with
lassiﬁcation of patients as hypertensive if systolic pres-
ure was above 140 mmHg  or diastolic above 90 mmHg  or if
hey were on antihypertensive treatment. A venous blood
ample was taken, after an overnight fasting (10 h) and
efore taking antidiabetic medication; biochemical measure-
ents included: blood glucose, glycosylated haemoglobin
HbA1c), creatinine, total cholesterol, and triglycerides. A
4 h urine sample was collected, and after excluding urinary
nfection, UAE was measured, with samples classiﬁed as nor-
oalbuminuria (<30 mg), microalbuminuria (30–300 mg), or
acroalbuminuria or proteinuria (>300 mg). Biochemistry was
easured with a Shimadzu CL 7200 auto-analyser. HbA1c was
easured with a Cobas Mira  Plus automatic analyser, with a
ormal range of 4.5–5.7%. UAE was measured using immuno-
urbidimetry on a Cobas Integra 700 analyser.
GFR was calculated in mL/min per 1.73 m2 using the CKD-
PI formula:
If (woman and creatinine ≤ 0.7) GFR = 144 * ([creatinine/
0.7] ** −0.329) * (0.993 ** age).
If (woman and creatinine > 0.7) GFR = 144 * ([creatinine/0.7] **
−1.209) * (0.993 ** age).
If (man and creatinine ≤ 0.9) GFR = 141 * ([creatinine/0.9] **
−0.411) * (0.993 ** age).
If (man and creatinine > 0.9) GFR = 141 * ([creatinine/0.9] **
−1.209) * (0.993 ** age).
GFR was categorised into 3 groups (≥60, 45–59, <45), as there
ere only 4 patients with a ﬁltrate <30 mL/min per 1.73 m2
ohort  follow-up
ll patients were prospectively followed up until their death
r date of study closure on 31 August 2012. Causes of death
ere obtained from the hospital clinical notes or by contac-
ing the general practitioner who signed the death certiﬁcate.
eaths were considered cardiovascular if they were sudden
eath, due to myocardial infarction, due to end stage heart
ailure, or due to cerebrovascular disease. In 4 patients (0.9%),
t was not possible to determine their vital status and they
ere considered lost to follow-up.
tatistical  methods
uantitative variables are reported as mean and standard
eviation (SD), and qualitative variables are reported as fre-
uency distribution. Quantitative variables were compared
sing Student t test or the nonparametric Mann–Whitney test
time since onset of DM and triglycerides). For comparison of
ualitative variables, a chi-square test was used.
The primary outcome variable was overall mortality.
atients were stratiﬁed into 9 categories according to their GFR(5):487–492 489
and UAE. The category with GFR ≥ 60 and UAE < 30 was used
as the reference category.
Patients were followed up from their inclusion in the study
until leaving the study due to reaching the closing date,
death, or being lost to follow-up. The rates of the differ-
ent events are expressed per 1000 patient-year. Rates were
compared between the different categories considered using
Kaplan–Meier analysis and the log-rank test.
Subsequently, Cox-regression models were used, with cal-
culation of hazard ratios (HR) and 95% conﬁdence intervals
(CI), to assess the risk conferred by the presence of the
different categories of GFR and UAE, and their interaction. Uni-
variate and multivariate models were used, adjusting for age,
sex, smoking, presence of arterial hypertension, existing vas-
cular disease, cholesterol and triglycerides (introduced in a
logarithmic form), HbAlc, and time since onset of DM.  The
independent predictors of total mortality were determined
using a sequential elimination procedure. The improved pre-
dictive power assumed by inclusion of GFR + UAE in the models
was determined with Harrell’s C statistic. Associations with
a P value < .05 were considered statistically signiﬁcant. The
software used was SPSS version 22.0.
Results
Of 463 patients, 453 were included; in 10 patients there was
no information on GFR or UAE. Among patients included, 178
(39.3%) were men. Mean age was 64.9 years (SD 9.3 years) and
the mean time since onset of DM was 10.4 years (SD 7.5 years).
At the time of enrolment, 192 (42.4%) patients were on treat-
ment with insulin and 98 (21.6%) had evidence of vascular
disease.
Regarding GFR, 69.8% of patients had a
GFR ≥ 60 mL/min/1.73 m2, 23.4% had a GFR between 45 and
59 mL/min/1.73 m2, and 6.8% had a GFR < 45 mL/min/1.73 m2.
The prevalence of normo- micro- and macroalbuminuria was
70.9%, 23.1%, and 6%, respectively.
Over a median 13-year follow-up (interquartile range 6.5
years; minimum 1 month, maximum 17 years) there was a
total of 207 deaths (rate 39.5/1000), of which 74 were cardio-
vascular deaths (rate 14.1/1000). There was a signiﬁcant linear
trend in the progressive increase of overall mortality rates as
GFR deteriorated and UAE increased (P < .001) (Fig. 1).
Patient characteristics according to survival or non-
survival during follow-up are shown in Table 1. Compared
with patients who survived, the patients who  died were older
and had a longer time since onset of DM, higher prevalence
of initial insulin treatment, lower cholesterol levels, higher
prevalence of macroangiopathy, lower GFR, and higher UAE.
Table 2 shows the rates and HR for mortality according to
the GFR and UAE levels. The interaction between GFR and UAE
was not signiﬁcant. In multivariate analysis, the variables that
were independently associated with mortality risk, in order
of predictive power, were age (HR = 1.092, 2 = 77.1, P < .0001),
UAE (HR30–300 = 1.02 and HR>300 = 2.3, 2 = 11.6, P = .003), pres-
2ence of existing vascular disease (HR = 1.7,  = 9.9, P=.002),
active smoking (HR = 1.84, 2 = 6.9, P=.032), GFR (HR45–59 = 1.34
and HR<45 = 1.84, 2 = 6.4, P = .041), and initial cholesterol levels
(HR = 0.843, 2 = 4.9, P = .026).
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Fig. 1 – Estimated probability using Kaplan–Meier survival curves according to the combined categories of GFR and UAE
(P < .0001).
Table 1 – Patient characteristics according to survival during follow-up. The variables are reported as mean (SD) or
frequency distribution.
Total sample Did not die Died P HR (95% CI)
GFR 45–59 (%) 23.4 17.5 30.4 <.001 1.9 (1.4–2.7)
GFR <45 (%) 6.8 2 12.6 4.4 (2.9–6.8)
Microalbuminuria (%) 23.2 20.7 26.1 <.001 1.5 (1.1–2)
Macroalbuminuria (%) 6 2 10.6 3.6 (2.3–5.7)
Sex (% men) 39.3 36.2 43 ns 1.3(0.9–1.7)
Existing CVD (%) 21.6 15 29.5 <.001 1.9 (1.4–2.5)
Ischaemic heart disease (%) 10.4 8.5 12.6 ns 1.4(0.9–2.1)
CVE (%) 6.8 4.5 9.7 .029 1.9 (1.2–3)
LL ischaemia (%) 7.7 3.3 13 <.001 2.8 (1.9–4.2)
Smoking (% active) 11.6 11 12.3 ns 1.2(0.8–1.9)
HTN (%) 77.9 76 80.2 ns 1.2 (0.9–1.7)
Treatment with insulin (%) 42.5 47.3 65.2 <.001 1.4 (0.7–3.1)
Age (years) 64.9 (9.3) 61.5 (9) 69 (7.9) <.001 1.1(1.07–1.1)
Cholesterol (mmol/L)
mg/dL: divide by 0.0259
5.66  (1.03) 5.77 (1.05) 5.53 (1.02) .008 0.83 (0.73–0.95)
Triglycerides (mmol/L)
mg/dL: divide by 0.0113
1.54  (1.04) 1.54 (0.91) 1.55 (1.19) ns 1.022 (0.89–1.18)
BMI (kg/m2) 29.3  (4.7) 29.3 (4.7) 29.4 (4.7) ns 1(0.97–1.03)
HbA1c (%) 7.76 (1.5) 7.7 (1.46) 7.8 (1.7) ns 1.025 (0.94–1.12)
Time since onset of DM (years) 10.4 (7.5) 9.4 (6.8) 11.7 (8.1) .004 1.026 (1.008–1.044)
BMI, body mass index; CVD, cardiovascular disease; CVE, cerebrovascular event; CI, conﬁdence interval; GFR, glomerular ﬁltration rate in
mL/min/1.73 m2; HR, hazard ratio; HTN, hypertension; LL, lower limbs; UAE, urinary albumin excretion.
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Table 2 – Mortality rates per 1000 patient-years and mortality risk according to the combined GFR and UAE categories.
UAE < 30 UAE 30–300 UAE > 300 UAE < 30 UAE 30–300 UAE > 300
Rate/1000 patient-years HR (95% CI)
GFR ≥ 60 26.6 38.3 75 Reference 1.5 (1–2.2) 3.2 (1.5–6.6)
GFR 45–59 51.5 70.3 115.4 2 (1.4–2.9) 3 (1.7–5.1) 4.7 (1.5–15)
GFR < 45 114.3 80.2 141 5.1 (2.4–11) 3.6 (1.7–8) 7.1 (3.7–13)
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Harrell’s C statistic was 0.726 in the baseline mortality pre-
iction model, composed of age, sex, smoking status, presence
f arterial hypertension and existing vascular disease, choles-
erol and triglycerides, HbAlc, and time since onset of DM.
nclusion of GFR and UAE improved the predictive power for
ortality of the model (Harrell’s C statistic 0.741, P = .045 vs.
revious model).
iscussion
his prospective follow-up over a median of 13 years in a
ohort of 453 patients with type 2 diabetes has allowed us to
rove the prognostic signiﬁcance of the simultaneous inclu-
ion of GFR and UAE in predicting mortality risk.
The issue of diabetes as a risk of coronary heart disease has
een widely debated.1,11,12 In one benchmark epidemiological
tudy13 carried out by the Emerging Risk Factors Collabora-
ion (ERFC), with more  than 820,900 participants, the presence
f DM approximately doubled the mortality risk, with total
ortality rates of 29/1000 in men  and 23/1000 in women and
VM rates of 13/1000 in men  and 11/1000 in women with DM.
n our study, the mortality rate was higher (39/1000), which
ould be explained by the older age of our patients compared
ith the previous study (65 vs. 58 years). However, CVM in
ur study was 14/1000, similar to that described in the ERFC
ata.
One review4 of clinical trials with at least 1000 patients
ith type 2 DM in each study demonstrated that mortality
ate varied between studies, ranging from 2.8 to 84.2/1000
atient-years. Therefore, considering the high prevalence of
he disease,14 it is a challenge to accurately identify those
atients with DM that are at the most unfavourable extreme
f the vascular risk spectrum. One consistent ﬁnding4 is that
he higher mortality rates are observed in trials that include
atients with CKD. One study of 42,761 patients with type 2
iabetes followed over 4 years15 demonstrated a synergistic
nteraction between low GFR and high UAE on mortality risk. In
ur study, as in the previously mentioned study, both GFR and
AE were independent predictive factors for mortality risk,
nd furthermore, they improved the predictive power of the
odels; the fact that the interaction term did not reach sta-
istical signiﬁcance could be due to the relatively low number
f patients included. Besides age, other factors signiﬁcantly
ssociated with mortality risk in our patients, were similar to
hose described in the literature: presence of existing vascu-
ar disease,1,16 low cholesterol levels (probably as a marker of
17 18eakness) and active smoking.
As in the general population, in patients with DM there
s a progressive increase in mortality risk as GFR decreases
nd UAE increases.19 Our data support this fact in a prolongedHR, hazard ratio; UAE, 24 h urinary albumin excretion.
follow-up of more  than 10 years. The possible pathophysiolo-
gical mechanisms that explain the association between CKD
and mortality include the increased prevalence of HTN and
left ventricular hypertrophy, the increased activity of both the
sympathetic system and renin–aldosterone system, endothe-
lial dysfunction, low grade inﬂammation, and high levels of
asymmetric dimethylarginine.20 It must also be kept in mind
that the changes over time in both GFR21 and UAE22 offer addi-
tional prognostic information.
The greatest strength of our study was the long follow-up of
patients, with only few losses, which allowed a reliable estima-
tion of mortality rates during this period of time and reinforced
the internal validity. The results are in agreement with those
obtained in a previous data analysis with a shorter follow-
up.23 Regarding noteworthy weaknesses, we  must point out
the limited number of subjects, with a low number of events
in some categories, which makes the estimations less precise.
Also, this study included patients with type 2 DM selected from
hospital outpatient clinics, with a mean age of 65 years and a
mean time since onset of DM of more  than 10 years, which lim-
its the external validity of the results. Finally, there were few
patients with GFR < 45, therefore the conclusions are primarily
valid for stages 1–3A of CKD.
We can conclude that GFR and UAE are independent pre-
dictors, without signiﬁcant interaction, of mortality risk in
patients with type 2 diabetes. We consider the systematic
assessment of both parameters fundamental in the follow-up
of patients with type 2 diabetes.
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